<DOC>
	<DOCNO>NCT02625259</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability new tablet formulation MLN1117 ( NTM ) compare MLN1117 Process B capsule ( CTM ) ( Part 1 ) , assess effect food oral bioavailability pharmacokinetics ( PK ) MLN1117 ( Part 2 ) , assess effect gastric pH-modifying agent PK MLN1117 healthy participant ( Part 3 ) .</brief_summary>
	<brief_title>A Study Evaluate Relative Bioavailability , Effect Food , Gastric pH Modification Pharmacokinetics MLN1117 Healthy Participants</brief_title>
	<detailed_description>The drug test study call MLN1117 . MLN1117 test treat people advance solid tumor . This study look PK relative bioavailability new tablet formulation MLN1117 compare current capsule formulation Part 1 . In Part 2 Part 3 , interaction MLN1117 food gastric pH modify agent evaluate respectively healthy participant , commence completion Part 1 . The study enroll approximately 54 participant . In Part 1 , participant randomly assign ( chance , like flip coin ) 1 2 crossover sequence : - Sequence A : MLN1117 capsule ( 9*100 mg ) first MLN1117 tablet ( 3*300 mg ) - Sequence B : MLN1117 tablet ( 3*300 mg ) first MLN1117 capsule ( 9*100 mg ) Part 2 Part 3 evaluate new tablet formulation MLN1117 dose determine Part 1 . In Part 2 , participant randomly assign receive single dose MLN1117 fast state follow MLN1117 standard high-fat breakfast Sequence A vice-versa Sequence B . In Part 3 , participant receive single dose MLN1117 Day 1 follow lansoprazole 30 mg Day 10 6 day second dose MLN1117 Day 15 . Blood sample collect predose 72 hour postdose prespecified time point Days 1 15 . Urine sample collect predose , 0 12 hour , 12 24 hour postdose Part 1 . This single center trial conduct United States . The overall time participate study approximately 45 day . Participants make 2 visit clinic part , remain confined clinic 4 10 day period drug dose study procedure . Participants also complete final visit 30 33 day last dose study drug follow-up assessment ( Day 45 ) .</detailed_description>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . Is age 18 45 year inclusive , time consent . 2 . Is healthy adult male female . 3 . Weighs great equal ( &gt; = ) 45 kilogram ( kg ) ( female ) &gt; =55 kg ( male ) , body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive , screen . 4 . Suitable venous access studyrequired blood sampling , include PK sampling . 5 . Has provide voluntary write consent . 1 . Any clinically significant abnormality screen medical history cardiac , hepatic , renal , respiratory , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 2 . Manifestations malabsorption due prior GI surgery , GI disease , unknown reason may alter PK MLN1117 lansoprazole . 3 . Creatinine clearance less equal ( &lt; = ) 90 milliliter ( mL ) /min base either CockroftGault estimate base 12 24hour urine collection screening . 4 . Known intolerance MLN1117 lansoprazole , excipients either drug . 5 . A positive test result human immunodeficiency virus ( HIV ) , hepatitis A antibody ( HAVAb ) , hepatitis B surface antigen ( HBsAg ) , hepatitis B core ( HBc ) antibody AntiHBc ( IgM ) , hepatitis C antibody ( HCVAb ) test screen , serological reaction syphilis screen . 6 . Has Lactose intolerance ( Part 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>